{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:28:03Z","timestamp":1785788883994,"version":"3.56.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1097\/01.wnf.0000135478.70905.3d","type":"journal-article","created":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T11:58:43Z","timestamp":1094039923000},"page":"171-177","source":"Crossref","is-referenced-by-count":23,"title":["Levetiracetam Interferes With the l-Dopa Priming Process in MPTP-Lesioned Drug-Naive Marmosets"],"prefix":"10.1097","volume":"27","author":[{"given":"Michael P","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R","family":"Crossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Bezard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Grim\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Klitgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210203","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1212\/WNL.40.2.340","article-title":"Levodopa-induced dyskinesia: review, observations, and speculations.","volume":"40","author":"Nutt","year":"1990","journal-title":"Neurology"},{"key":"R2-5-20210203","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00002826-199704000-00001","article-title":"Strategies for treating patients with advanced Parkinsons disease with disastrous fluctuations and dyskinesias.","volume":"20","author":"Stocchi","year":"1997","journal-title":"Clin Neuropharmacol"},{"key":"R3-5-20210203","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","article-title":"Modification of Parkinsonism: chronic treatment with L-dopa.","volume":"280","author":"Cotzias","year":"1969","journal-title":"N Engl J Med"},{"key":"R4-5-20210203","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinsons disease who were treated with ropinirole or levodopa.","volume":"342","author":"Rascol","year":"2000","journal-title":"N Engl J Med"},{"key":"R5-5-20210203","first-page":"S179","article-title":"Medical treatment of levodopa-induced dyskinesias.","volume":"47","author":"Rascol","year":"2000","journal-title":"Ann Neurol"},{"key":"R6-5-20210203","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.","volume":"2","author":"Bezard","year":"2001","journal-title":"Nat Rev Neurosci"},{"key":"R7-5-20210203","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/mds.870130603","article-title":"Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinsons disease.","volume":"13","author":"Brotchie","year":"1998","journal-title":"Mov Disord"},{"key":"R8-5-20210203","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/ajp.143.1.118a","article-title":"Naloxone treatment of l-dopa-induced dyskinesias in Parkinsons disease.","volume":"143","author":"Sandyk","year":"1986","journal-title":"Am J Psychiatry"},{"key":"R9-5-20210203","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinsons disease.","volume":"50","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"R10-5-20210203","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1212\/WNL.30.12.1257","article-title":"Drug holiday and management of Parkinson disease.","volume":"30","author":"Weiner","year":"1980","journal-title":"Neurology"},{"key":"R11-5-20210203","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00002826-198212000-00003","article-title":"Drug holiday in the management of Parkinson disease.","volume":"5","author":"Goetz","year":"1982","journal-title":"Clin Neuropharmacol"},{"key":"R12-5-20210203","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0920-1211(01)00287-X","article-title":"Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review.","volume":"46","author":"Marson","year":"2001","journal-title":"Epilepsy Res"},{"key":"R13-5-20210203","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1212\/WNL.56.12.1772","article-title":"Long-term continuation of levetiracetam in patients with refractory epilepsy.","volume":"56","author":"Krakow","year":"2001","journal-title":"Neurology"},{"key":"R16-5-20210203","first-page":"S122","article-title":"Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.","volume":"47","author":"Chase","year":"2000","journal-title":"Ann Neurol"},{"key":"R17-5-20210203","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/mds.1148","article-title":"Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.","volume":"16","author":"Fox","year":"2001","journal-title":"Mov Disord"},{"key":"R18-5-20210203","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7","article-title":"The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of l-dopa in the MPTP-lesioned primate model of Parkinsons disease.","volume":"14","author":"Henry","year":"1999","journal-title":"Mov Disord"},{"key":"R19-5-20210203","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","article-title":"Chronic l-dopa administration induces dyskinesias in the MPTP-treated common marmoset (Callithrix Jacchus).","volume":"10","author":"Pearce","year":"1995","journal-title":"Mov Disord"},{"key":"R20-5-20210203","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/mds.10289","article-title":"Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinsons disease.","volume":"17","author":"Fox","year":"2002","journal-title":"Mov Disord"},{"key":"R21-5-20210203","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1006\/exnr.2001.7727","article-title":"Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinsons Disease.","volume":"171","author":"Henry","year":"2001","journal-title":"Exp Neurol"},{"key":"R22-5-20210203","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ana.410430415","article-title":"Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys.","volume":"43","author":"Kanda","year":"1998","journal-title":"Ann Neurol"},{"key":"R23-5-20210203","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/mds.10200","article-title":"Repeated administration of piribedil induces less dyskinesia than l-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.","volume":"17","author":"Smith","year":"2002","journal-title":"Mov Disord"},{"key":"R24-5-20210203","first-page":"S90","article-title":"Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates.","volume":"47","author":"Jenner","year":"2000","journal-title":"Ann Neurol"},{"key":"R25-5-20210203","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00726-001-0116-4","article-title":"Transcription factors involved in the pathogenesis of l-DOPA-induced dyskinesia in a rat model of Parkinsons disease.","volume":"23","author":"Cenci","year":"2002","journal-title":"Amino Acids"},{"key":"R26-5-20210203","first-page":"S70","article-title":"Molecular basis of levodopa-induced dyskinesias.","volume":"47","author":"Calon","year":"2000","journal-title":"Ann Neurol"},{"key":"R27-5-20210203","first-page":"S189","article-title":"Dyskinesias and the subthalamic nucleus.","volume":"47","author":"Benabid","year":"2000","journal-title":"Ann Neurol"},{"key":"R28-5-20210203","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(95)90062-4","article-title":"Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation.","volume":"345","author":"Limousin","year":"1995","journal-title":"Lancet"},{"key":"R29-5-20210203","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0301-0082(01)00033-8","article-title":"From single extracellular unit recording in experimental and human Parkinsonism to the development of a functional concept of the role played by the basal ganglia in motor control.","volume":"66","author":"Boraud","year":"2002","journal-title":"Prog Neurobiol"},{"key":"R30-5-20210203","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S1059131102001930","article-title":"Electrophysiological, neurochemical and regional effects of levetiracetam in the rat pilocarpine model of temporal lobe epilepsy.","volume":"12","author":"Klitgaard","year":"2003","journal-title":"Seizure"},{"key":"R31-5-20210203","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1006\/phrs.2000.0689","article-title":"Inhibition of neural hypersynchrony in vitro differentiates levetiracetam from classic antiepileptic drugs.","volume":"42","author":"Margineanu","year":"2000","journal-title":"Pharmacol Res"},{"key":"R33-5-20210203","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0014-2999(98)00410-5","article-title":"Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy.","volume":"353","author":"Klitgaard","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"R34-5-20210203","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(01)01884-5","article-title":"Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices.","volume":"306","author":"Niespodziany","year":"2001","journal-title":"Neurosci Lett"},{"key":"R35-5-20210203","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1528-1157.2002.24501.x","article-title":"Selective blockade of N-type calcium channels by levetiracetam.","volume":"43","author":"Lukyanetz","year":"2002","journal-title":"Epilepsia"},{"key":"R36-5-20210203","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/sj.bjp.0704766","article-title":"The anti-epileptic drug levetira-cetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents.","volume":"136","author":"Rigo","year":"2002","journal-title":"Br J Pharmacol"},{"key":"R37-5-20210203","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0014-2999(95)00436-O","article-title":"The novel antiepileptic drug levetiracetam (UCB L059) appears to act via a specific binding site in CNS membranes.","volume":"286","author":"Noyer","year":"1995","journal-title":"Eur J Pharmacol"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.wnf.0000135478.70905.3d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:35:10Z","timestamp":1785785710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-200407000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1097\/01.wnf.0000135478.70905.3d","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}